Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.40 |
| ▸ | CA7 | P43166 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | METAP1 | P53582 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL275618 | 0.81 | CA2 (0.38) | CA2CA1CA14CA7CA12 | |
| SCHEMBL20404468 | 0.79 | CA2 (0.39) | CA2CA1CA14CA7CA9 | |
| SCHEMBL276314 | 0.79 | CA2 (0.39) | CA2CA1CA14CA7CA9 | |
| SCHEMBL1704349 | 0.79 | CA12 (0.33) | CA2CA1CA14CA7CA12 | |
| SCHEMBL277730 | 0.76 | CA2 (0.38) | CA2CA1CA14CA7CA12 | |
| SCHEMBL18674541 | 0.75 | TP53 (0.40) | CA2CA1CA14CA7CA12 | |
| SCHEMBL222996 | 0.74 | — | — | |
| SCHEMBL22811253 | 0.74 | — | — | |
| SCHEMBL20629643 | 0.73 | MMP9 (0.33) | CA2CA1CA14CA7CA12 | |
| SCHEMBL17542216 | 0.73 | MMP9 (0.33) | CA2CA1CA14CA7CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10344016-B2 | Bromotriazole intermediates | AMGEN INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | AMGEN INC. (US) | 2019-04-04 | — | — | US | disclosed |
| US-10221162-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-10058550-B2 | Methods of treating heart failure | AMGEN INC. (US) | 2018-08-28 | — | — | US | disclosed |
| US-9868721-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9845310-B2 | Intermediates for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-12-19 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-9751864-B2 | Methods for preparing triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-09-05 | — | — | US | disclosed |
| US-9745286-B2 | Triazole agonists of the APJ receptor | AMGEN INC. (US) | 2017-08-29 | — | — | US | disclosed |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2010-10-21 | — | — | US | disclosed |
| EP-2233468-A1 | OPTICALLY ACTIVE DINICKEL COMPLEX AND METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE USING THE OPTICALLY ACTIVE DINICKEL COMPLEX AS CATALYST | Nissan Chemical Industries, Ltd. (JP) | 2010-09-29 | — | — | EP | disclosed |
| EP-2228435-A1 | METHOD FOR AMPLIFICATION OF HEMATOPOIETIC STEM CELL USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-09-15 | — | — | EP | disclosed |
| EP-2218716-A1 | METHOD FOR AMPLIFYING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | Nissan Chemical Industries, Ltd. (JP) | 2010-08-18 | — | — | EP | disclosed |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-08-06 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| EP-2025671-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2009-02-18 | — | — | EP | disclosed |
| EP-1947101-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2008-07-23 | — | — | EP | disclosed |
| EP-1845090-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | Nissan Chemical Industries, Ltd. (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180319773-A1 | TRIAZOLE AGONISTS OF THE APJ RECEPTOR | TBXA2R, AGTR1, AGTR2 | CA2 1571/4885CA1 4264/4885CA14 4737/4885 |
| US-20190100510-A1 | BROMOTRIAZOLE INTERMEDIATES | APH1A, BRDT, APH1B | CA2 4528/4885CA1 3788/4885CA14 4317/4885 |
| US-20100266556-A1 | METHOD FOR EXPANDING HEMATOPOIETIC STEM CELLS USING HETEROCYCLIC COMPOUND | HCLS1, RUNX1, ACIN1 | CA2 4551/4885CA1 4256/4885CA14 4610/4885 |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | CA2 3065/4885CA1 2999/4885CA14 3882/4885 |
| US-10058550-B2 | Methods of treating heart failure | FABP3, TNNI3, APLNR | CA2 341/4885CA1 1133/4885CA14 3828/4885 |
| US-10344016-B2 | Bromotriazole intermediates | APH1A, BRDT, APH1B | CA2 4528/4885CA1 3788/4885CA14 4317/4885 |
| US-20090198060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, MPL, IL1RN | CA2 2806/4885CA1 2865/4885CA14 3593/4885 |
| US-10221162-B2 | Triazole agonists of the APJ receptor | TBXA2R, AGTR1, AGTR2 | CA2 1571/4885CA1 4264/4885CA14 4737/4885 |
| US-20090253751-A1 | HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, THPO, PTAFR | CA2 1765/4885CA1 2064/4885CA14 2783/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | CA2 341/4885CA1 1133/4885CA14 3828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.